Conclusions TACE plus targeted immunotherapy yields high response and surgical conversion rates with acceptable toxicity in uHCC. Patients with CNLC stage Ib–IIa, <3 tumors, no major vascular invasion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback